Eslikarbazepin asetat: Perbedaan antara revisi
Konten dihapus Konten ditambahkan
Tidak ada ringkasan suntingan Tag: Suntingan perangkat seluler Suntingan peramban seluler Suntingan seluler lanjutan |
Tidak ada ringkasan suntingan Tag: Suntingan perangkat seluler Suntingan peramban seluler Suntingan seluler lanjutan |
||
Baris 69:
Mirip dengan [[okskarbazepin]], ESL berfungsi sebagai obat pendahulu (''S'')-(+)-[[likarbazepin]].<ref name="pmid16621450">{{cite journal | vauthors = Rogawski MA | title = Diverse mechanisms of antiepileptic drugs in the development pipeline | journal = Epilepsy Research | volume = 69 | issue = 3 | pages = 273–94 | date = June 2006 | pmid = 16621450 | pmc = 1562526 | doi = 10.1016/j.eplepsyres.2006.02.004 }}</ref> Dengan demikian, [[mekanisme aksi|mekanisme kerja]] keduanya identik.<ref name="pmid15208697">{{cite journal | vauthors = Rogawski MA, Löscher W | title = The neurobiology of antiepileptic drugs | journal = Nature Reviews. Neuroscience | volume = 5 | issue = 7 | pages = 553–64 | date = July 2004 | pmid = 15208697 | doi = 10.1038/nrn1430 | s2cid = 2201038 | url = https://zenodo.org/record/1233562 }}</ref>
==Sejarah==
Eslikarbazepin asetat dikembangkan oleh perusahaan farmasi Portugis Bial. Pada awal tahun 2009, Bial menjual hak pemasaran di Eropa kepada perusahaan Jepang [[Eisai (perusahaan)|Eisai]].<ref>{{cite news |url= http://www.prnewswire.co.uk/news-releases/eisai-and-bial-announce-partnership-agreement-for-the-european-commercialisation-of-the-novel-once-daily-anti-epileptic-zebinixr-153037325.html|title=Eisai and Bial Announce Partnership Agreement for the European Commercialisation of the Novel Once Daily Anti-Epileptic Zebinix|publisher=PR Newswire|date=19 February 2009}}</ref> Obat ini disetujui di Uni Eropa pada bulan April 2009 dengan nama dagang Zebinix dan Exalief, tetapi dipasarkan hanya dengan nama depan.<ref>{{cite web|url=http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000988/WC500047225.pdf|title=Summary of Product Characteristics for Zebinix|publisher=[[European Medicines Agency]]|page=14|access-date=2016-05-22|archive-date=2018-09-20|archive-url=https://web.archive.org/web/20180920114125/http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000988/WC500047225.pdf|url-status=dead}}</ref><ref>{{cite web|url=http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2012/08/WC500130787.pdf|title=Exalief (eslicarbazepine acetate): Expiry of the marketing authorisation in the European Union|publisher=European Medicines Agency|date=30 July 2012|access-date=22 May 2016|archive-date=20 September 2018|archive-url=https://web.archive.org/web/20180920114129/http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2012/08/WC500130787.pdf|url-status=dead}}</ref> Di AS, obat ini dipasarkan oleh [[Sunovion]] (sebelumnya Sepracor) dan disetujui pada bulan November 2013.<ref name="FDA" />
==Kontraindikasi==
==Efek samping==
| |||